Department of Neonatal Paediatrics, KEM Hospital, Perth, WA, Australia
Department of Neonatal Paediatrics, Princess Margaret Hospital for Children, Perth, WA, Australia
Centre for Neonatal Research and Education, School of Paediatrics and Child Health, University of Western Australia, Perth, WA, Australia
Women and Infants Research Foundation, King Edward Memorial Hospital for Women, Perth, WA, Australia
School of Women’s and Infants’ Health, University of Western Australia, Perth, WA, Australia
Address for correspondence: Prof Sanjay Patole, FRACP, Department of Neonatal Paediatrics, King Edward Memorial Hospital for Women, 374 Bagot Rd, Subiaco WA 6008, Australia. Tel.: +6164582222; E-mail: [email protected].
Abstract: BACKGROUND:Excessive inflammation is associated with adverse outcomes in preterm infants. C- reactive protein (CRP) is a marker of inflammation/infection. Probiotics have anti-inflammatory properties. Randomized controlled trials (RCTs) in preterm infants have not reported effect of probiotics on CRP. AIM:To evaluate effect of probiotics on CRP in preterm infants who had participated in a RCT of Bifidobacterium breve (B. breve) m-16v. METHODS:Data on all infants (GA <33 weeks, n = 159) enrolled in the RCT was analyzed. For study purpose, CRP <15 mg/L and ≤10 mg/L was considered normal for the first week, and thereafter respectively. Mixed logistic regression modelling was used to assess probiotic effect on CRP levels. RESULTS:There were 1579 CRP measurements (Probiotic: 851 vs. Placebo: 728). Baseline characteristics and number [Median (IQR)] of CRP estimations per infant [l0 (5, 20) vs. 10 (6, 17), p = 0.861] were comparable between probiotic vs. placebo group. There was no significant difference in the proportion of infants with high CRP over time (treatment by weekly time points interaction, p = 0.187), and across all time points between probiotic and placebo group (adjusted OR: 1.62, 95% CI: 0.91–2.88, p = 0.102) CONCLUSION:B. breve m-16v did not decrease CRP levels in preterm infants born <33 weeks.
Keywords: C-reactive protein, inflammation, preterm infant, probiotic, Bifidobacterium breve